New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s ...
Gliomas are the most prevalent and aggressive primary brain tumors, characterized by profound tumor heterogeneity, poor prognosis, and limited therapeutic ...
Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million -- -- December 20, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback